DXSP DXS International Plc

 
TIDMDXSP 
 
 
   DXS INTERNATIONAL PLC 
 
   (AQSE: DXSP) 
 
   Selection to participate in Research Project 
 
   DXS International plc ("DXSP" or the "Company"), the AQSE quoted 
clinical decision support developer and supplier of clinical decision 
support systems, is pleased to announce that it has been selected to 
receive a grant to take part in a Pre-Commercial Procurement project by 
HSMonitor. 
 
   HSMonitor is a Pre-Commercial Procurement (PCP) project investing in 
Research and Development services towards innovative ICT-enabled 
monitoring solutions to improve health status and optimise hypertension 
care. The initiative is funded by the European Union's Horizon Research 
and Development programme that seeks to drive and support innovation in 
member states. Five healthcare providers 
https://www.globenewswire.com/Tracker?data=-supKSL0h5kvOec7bBl-6t1XdYQqD0b52hOriMcsL33zcl87YqMkEQCde13mARer-tdDrUY3qz55WExHkg6BDF_fl6E9Icxgjugwe9yFaU0cvEXI9cA_jglu2ZBQbDeC 
from four countries are engaged in the procurement, catering to a 
combined population of over 96 million people, of which over 31 million 
have hypertension. 
 
   A Call for Tenders was launched in August 2020, calling for innovative 
ideas to be proposed. A total of 18 Tenders were submitted to the Call, 
representing 70 participating entities from 16 countries, the majority 
of which represent Small and Medium-sized Enterprises (SMEs). Following 
a thorough evaluation of the submitted bids, seven projects were 
selected to proceed in Phase I of the R&D process. 
 
   The envisaged solutions are to be developed in three funded competitive 
phases and further detail can be found on the HSMonitor website 
https://hsmonitor-pcp.eu . The PCP is anticipated to roll out over a 
twenty-five month period. 
 
   Chief Executive David Immelman commented: 
 
   "I am delighted that the DXS' team's hard work, dedication and expertise 
have been rewarded by this selection in the face of stiff opposition. 
This is an exciting time for DXS to help improve patient outcomes by 
bringing our Long-Term Condition management healthcare solutions to a 
new market -- particularly as the next phase of development will now be 
supported by grant funding. Our Hypertension solution, in which we have 
invested over a number of years, will provide improved outcomes and 
significant efficiency savings for all hypertension sufferers in Europe, 
as well as for both GP Practices and the NHS in the UK. 
 
   While going forward to Phases II and III is by selection, we are 
confident that our expertise and depth of knowledge will ensure our 
offering is of the highest standard." 
 
   The Directors of DXS International plc accept responsibility for this 
announcement. 
 
   Contacts: 
 
 
 
 
David Immelman (Chief Executive)               01252 719800 
 DXS International plc                david@dxs-systems.com 
https://www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
City & Merchant 
 David Papworth     020 7101 7676 
 
 
 
 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 
 
   Notes to Editors 
 
   About DXS: 
 
   DXS International presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively and which should significantly contribute towards 
the NHS achieving its projected efficiency savings. 
 
 
 
 

(END) Dow Jones Newswires

March 04, 2021 07:12 ET (12:12 GMT)

DXS (AQSE:DXSP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

DXS (AQSE:DXSP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024